Biohaven to Present New Clinical Data at ESMO Congress on BHV-1530, a Novel FGFR3-Directed ADC With a Proprietary Topoisomerase I (TopoIx) Payload
Go back to Biohaven to Present New Clinical Data at ESMO Congress on BHV-1530, a Novel FGFR3-Directed ADC With a Proprietary Topoisomerase I (TopoIx) Payload| (NYSE: BHVN) | Delayed: 14.75 -0.76 (4.9%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $15.51 | 52 Week High | $ | |||
| Open | $15.26 | 52 Week Low | $ | |||
| Day High | $15.50 | P/E | N/A | |||
| Day Low | $14.56 | EPS | $ | |||
| Volume | 2,169,531 | |||||
